Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.
about
P1343
Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitinationPhysical and functional interaction of androgen receptor with calmodulin in prostate cancer cellsAndrogen receptor molecular biology and potential targets in prostate cancerSmall molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancerMolecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsAndrogen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survivalAcquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation.Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer CellsThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceA novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growthDifferential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptorDevelopment and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.Transcriptional activity of c-Jun is critical for the suppression of AR function.The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancerC/EBPalpha redirects androgen receptor signaling through a unique bimodal interactionCalmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cellsSIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas.Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosisAndrogen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signalingCR6-interacting factor 1 represses the transactivation of androgen receptor by direct interaction.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth.Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activityThe ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cellsInhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reductionSlug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression.miR 488* inhibits androgen receptor expression in prostate carcinoma cellsSNRPE is involved in cell proliferation and progression of high-grade prostate cancer through the regulation of androgen receptor expression.Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathwaysRole of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase.Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements.Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.Diabetes protects from prostate cancer by downregulating androgen receptor: new insights from LNCaP cells and PAC120 mouse model.Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
P2860
Q24312829-59A78A00-8A0C-480D-AA0E-504AAC2B347EQ24598075-01EBC83C-172D-4301-9282-713C90A0CAA4Q24602861-B13C1CE3-F399-495F-BAA9-9906775D8312Q24620356-F0D0CE04-556E-485C-8B4F-B9F3903B53C2Q24629083-22EF2CF8-FC3D-4387-9236-14D2B1E75E74Q24793296-21073497-04EC-41E1-93E6-A62C7CD382D9Q24815477-0F58965F-8206-422F-A34A-165FFDE9C8F2Q26795738-F10B1E7A-6E27-4ED4-AF88-CC2BC1E8FB79Q28076745-EE21C70A-CC8D-499C-94FD-23F84CCDFC7CQ28116222-2D8D9B47-8CA8-461A-9F64-2584EDD591AEQ28534575-FADBED2C-087F-402A-9A63-CA377015C342Q30276797-A2DF3822-0A48-4210-82C1-593F43AE7943Q30412500-B2A0C57D-C144-49E2-80E6-484B449ABF5FQ30434799-8894DE3B-EAA0-477F-85FF-28554E855778Q30440162-B04E3EFE-BD84-4849-A5CC-F435A8077920Q30446961-EE44FDE1-7B11-4429-99BA-7A6B512CA893Q30500293-702A778B-88BE-466D-A06A-7ED4CBCA2370Q33302103-51D9C66A-ADC7-410C-A450-E9643AF48F2EQ33363331-B955E3AF-02D8-459F-94D5-28722758A6DDQ33607836-A730FF63-7B36-44A4-B110-F69575B6AF25Q33632245-DC0EEAE3-7868-4100-9450-CA5FCCC232F1Q33643292-BE3BC4C6-608F-4871-9D94-30249008B622Q33775717-26EF0D27-B954-456B-B501-B8710664F057Q33803841-A7EE40DA-C7D0-4E60-A253-2E78374E96F2Q33810134-91FE3B74-5C7E-48BB-9CAB-42F183D58D3DQ33896008-8E1DB5A4-45AB-4639-9DBB-AD8D7CA4F8A7Q33896203-DFC16FE8-5BA3-46DE-A384-D2124654A2A9Q34022799-E0277C14-300B-47B4-921C-2CC6EC7A2CCAQ34043113-AFB7A6E9-20E4-477D-A7FF-EDCF832F780FQ34124650-4E7927EA-8E50-48D9-A395-7BA8C25264ACQ34127128-1739F3B7-9BFD-4F6D-87D4-31536F1ABEC7Q34148084-CA249C05-D72D-471C-A9CC-F3DD9CC272E6Q34196086-AA030D76-21CC-445B-B7BF-9F0798AAA8E5Q34319619-5C0EB52F-42AB-45BC-9481-3444C13A8240Q34558936-3D216DFB-8A1B-4623-ABC7-0577E4F16E8DQ34599285-94CC10BC-F5F8-474B-8A4B-C6095BFD3D61Q34712118-FCAB9C9B-1912-4A34-81D1-803C686E3D21Q34786897-4413C588-72F9-4971-8FDD-40C8DDF53299Q34994538-7D7653FB-EC03-44FA-92E7-B783F2D5E7A7Q35083279-BD7E36D9-D6FD-4184-B690-38BFF32A23C7
P2860
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Disruption of androgen recepto ...... ractory prostate cancer cells.
@en
Disruption of androgen recepto ...... ractory prostate cancer cells.
@nl
type
label
Disruption of androgen recepto ...... ractory prostate cancer cells.
@en
Disruption of androgen recepto ...... ractory prostate cancer cells.
@nl
prefLabel
Disruption of androgen recepto ...... ractory prostate cancer cells.
@en
Disruption of androgen recepto ...... ractory prostate cancer cells.
@nl
P2093
P1433
P1476
Disruption of androgen recepto ...... ractory prostate cancer cells.
@en
P2093
Donald J Tindall
Haojie Huang
Lucy J Schmidt
Ofelia L Zegarra-Moro
P304
P407
P4510
P577
2002-02-01T00:00:00Z